Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.

Thermo Fisher found that its blood tests could monitor the changing genetics of lung tumors and illustrate developments in drug resistance over time.

Grail’s multicancer blood test has taken a helpful step closer to approval, by obtaining a breakthrough device designation from the FDA.

Zebra Medical received an FDA go-ahead to use AI to quickly scour X-rays and alert clinicians for signs of pneumothorax.

Pulmonx has secured $65 million in new equity financing for its global commercialization efforts through a round led by Ally Bridge Group.

The cryoablation therapy will featuring an integrated, real-time guidance system for the treatment of atrial fibrillation.

Medtronic walked away from Responsive Orthopedics, which it bought three years ago to disrupt the knee replacement market with cheaper joints.

Medical device cybersecurity provider MedCrypt raised $5.3 million, with plans to expand its team with new sales and software engineering positions.